# A Novel Microencapsulated Bovine Recombinant Interferon Tau Formulation for Luteolysis Modulation in Cattle

**Authors:** Emilio Lamazares, Aleikar Vásquez, Kelly Gancino, Felipe Sandoval, Javiera Yáñez-Torres, Miguel A. Gutierrez-Reinoso, Manuel García-Herreros, Paula Gädicke, Ignacio Cabezas, Florence Hugues, Thelvia I. Ramos, Frank Camacho, Karel Mena-Ulecia, Jorge R. Toledo

PMC · DOI: 10.3390/biom15071009 · 2025-07-14

## TL;DR

A new formulation of bovine interferon tau was developed to improve cattle reproduction by preventing premature luteolysis through sustained release.

## Contribution

A novel microencapsulated and hydrogel-based delivery system for recombinant bovine IFN-τ with sustained release and biological efficacy.

## Key findings

- The rbIFN-τ formulation showed sustained release in vitro for up to 26 days.
- Treated cattle exhibited inhibited luteolysis and sustained progesterone levels.
- The formulation stimulated interferon-stimulated genes and retained antiviral activity.

## Abstract

Early embryonic loss is a major cause of reproductive inefficiency in cattle, primarily due to premature luteolysis. Interferon tau (IFN-τ), secreted by the trophoblast, plays a critical role in maternal recognition of pregnancy by maintaining corpus luteum function. However, its practical application has been limited by its rapid degradation and short half-life in vivo. Here, we developed a novel formulation of recombinant bovine IFN-τ, combining chitosan-based microencapsulation with starch–chitosan hydrogel delivery, enabling sustained intrauterine release. This dual-delivery strategy offers a significant improvement over conventional IFN-τ administration methods that rely on repeated intrauterine infusions of soluble protein. The rbIFN-τ was expressed in Pichia pastoris, purified to 90.1% homogeneity, and structurally validated via homology modeling and molecular docking, confirming its interaction with type I interferon receptors. The encapsulated formulation retained antiviral activity, stimulated transcription of interferon-stimulated genes (PKR, OAS1, OAS2), and showed sustained release in vitro for up to 26 days. In vivo evaluation demonstrated safety and biological efficacy, with treated cattle showing inhibited luteolysis, sustained serum progesterone levels, and preserved corpus luteum integrity. This formulation represents a promising biotechnological approach to improve reproductive efficiency through a long-acting, species-specific IFN-τ delivery system.

## Linked entities

- **Genes:** EIF2AK2 (eukaryotic translation initiation factor 2 alpha kinase 2) [NCBI Gene 5610], OAS1 (2'-5'-oligoadenylate synthetase 1) [NCBI Gene 4938], OAS2 (2'-5'-oligoadenylate synthetase 2) [NCBI Gene 4939]
- **Proteins:** IFNT (interferon-tau 3g)
- **Chemicals:** chitosan (PubChem CID 129662530), progesterone (PubChem CID 5994)

## Full-text entities

- **Genes:** EIF2AK2 (eukaryotic translation initiation factor 2 alpha kinase 2) [NCBI Gene 347700] {aka PKR, PRKR}, IFNT2 (interferon tau) [NCBI Gene 317698] {aka IFN-tau-c2, IFNT, IFNT1, TP-1}, OAS1Z (2',5'-oligoadenylate synthetase 1, 40/46kDa) [NCBI Gene 519922] {aka OAS1}, OAS2 (2'-5'-oligoadenylate synthetase 2) [NCBI Gene 529660]
- **Diseases:** embryonic loss (MESH:D020964)
- **Chemicals:** progesterone (MESH:D011374), chitosan (MESH:D048271), starch (MESH:D013213)
- **Species:** Bos taurus (bovine, species) [taxon 9913]

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12293041/full.md

---
Source: https://tomesphere.com/paper/PMC12293041